Kennedy Capital Management, Inc. Krystal Biotech, Inc. Transaction History
Kennedy Capital Management, Inc.
- $4.35 Billion
- Q2 2024
A detailed history of Kennedy Capital Management, Inc. transactions in Krystal Biotech, Inc. stock. As of the latest transaction made, Kennedy Capital Management, Inc. holds 4,957 shares of KRYS stock, worth $876,843. This represents 0.02% of its overall portfolio holdings.
Number of Shares
4,957
Previous 2,901
70.87%
Holding current value
$876,843
Previous $516,000
76.36%
% of portfolio
0.02%
Previous 0.01%
Shares
6 transactions
Others Institutions Holding KRYS
# of Institutions
275Shares Held
24.9MCall Options Held
270KPut Options Held
172K-
Black Rock Inc. New York, NY3.95MShares$698 Million0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.87MShares$508 Million0.01% of portfolio
-
Avoro Capital Advisors LLC New York, NY2.43MShares$430 Million6.1% of portfolio
-
State Street Corp Boston, MA1.33MShares$236 Million0.01% of portfolio
-
Redmile Group, LLC San Francisco, CA1.02MShares$181 Million12.22% of portfolio
About Krystal Biotech, Inc.
- Ticker KRYS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 25,664,300
- Market Cap $4.54B
- Description
- Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa. The company is also involved in developing ...